A recent phase III clinical trial (SPOTLIGHT) evaluated the efficacy and safety of zolbetuximab plus mFOLFOX6 (modified folinic acid, fluorouracil, and oxaliplatin regimen, ZOL-FO) as the first-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic G/GEJ adenocarcinoma (Shitara et al., 2023). Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.